Cannabis Movers Shakers: Newscope Capital, Mr. Cannabis Law, CannTrust, Nabis, AMMJ, Plus Products, Christina Lake Depression Researcher Joins Newscope Capital’s PharmaTher Newscope Capital Corporation (CSE:PHRM) (OTCQB: PHRRF ) has appointed Dr. Maurizio Fava, MD, through its subsidiary PharmaTher Inc., to serve as a scientific and clinical advisor for clinical research initiatives with KETABET, a treatment option for depression. Besides serving as psychiatrist-in-chief at the Massachusetts General Hospital, Fava is also a director at Division of Clinical Research of the MGH Research Institute, executive director of the Clinical Trials Network and Institute, associate dean for clinical and translational research, and the Slater Family Professor of Psychiatry at Harvard Medical School, Psychedelic Finance writes . Fava said Tuesday he is looking forward to collaborating with PharmaTher. “There is a significant unmet medical need for new therapeutics for depression, and ketamine, with its limitations, is an attractive treatment option,” he added. Mr. Cannabis Law Taps New Senior Associate Attorney Cannabis-focused full-service law firm Mr.